Comparative clinicopathological and outcome analysis of differentiated thyroid cancer in Saudi patients aged below 60 years and above 60 years

• Published in: Clinical interventions in aging 2016-01, Vol.11, p.1169-1174
• Main Authors: Al-Qahtani, Khalid Hussain, Tunio, Mutahir A, Asiri, Mushabbab Al, Bayoumi, Yasser, Balbaid, Ali, Aljohani, Naji J, Fatani, Hanadi
• Format: Article
• Language: English
• Subjects: Age; age below 60 years; Age Factors; Aged; aged above 60 years; Aged, 80 and over; Cancer therapies; Care and treatment; clinicopathological characteristics; Differentiated thyroid cancers; Disease; Disease-Free Survival; elderly patients. comparative analysis; Female; Food Contamination, Radioactive; Geriatrics; Humans; Hypocalcemia; Iodine; Iodine Radioisotopes - therapeutic use; Kaplan-Meier Estimate; Lymphatic system; Male; Medical imaging; Metastasis; Middle Aged; Neck; Older people; Oncology; Original Research; Patients; patients aged above 45 years; Postoperative Complications - epidemiology; Postoperative Hemorrhage; Retrospective Studies; Saudi Arabia; Surgery; Thyroid cancer; Thyroid Neoplasms - classification; Thyroid Neoplasms - therapy; Thyroidectomy; Thyrotropin; Thyrotropin - antagonists & inhibitors; Treatment Outcome; treatment outcomes
• ISSN: 1178-1998; 1176-9092; 1178-1998
• DOI: 10.2147/CIA.S107881

The aim of this study was to evaluate the treatment outcomes of differentiated thyroid cancer in Saudi patients aged above 60 years. Comparative analysis was performed in 252 patients aged 46-60 years (Group A) and 118 patients aged above 60 years (Group B), who had thyroidectomy, radioactive iodine-131, and thyroid-stimulating hormone suppression therapy between July 2000 and December 2012. Different clinicopathological features, treatment, complications, disease-free survival, and overall survival rates were compared. Mean age of patients in Group A was 51.9 years (range: 46-60), and mean age of those in Group B was 68.6 years (range: 62-97). Group B patients had higher positive lymph nodes (43.2%), P=0.011. The frequency of extrathyroidal extension, multifocality, and lymphovascular space invasion was seen more in Group B than in Group A. Postsurgical complications (permanent hypoparathyroidism, bleeding, and wound infections) were also seen more in Group B (P=0.043, P=0.011, and P=0.021, respectively). Group B patients experienced more locoregional recurrences (11.0%, P=0.025); similarly, more distant metastases were observed in Group B (15.3%, P=0.003). The 10-year disease-free survival rates were 87.6% in Group A and 70.8% in Group B (P